Date of first round report: 1 September 2016 Date of second round report: 30 January 2017


Results for other efficacy outcomes



Download 5.49 Mb.
Page25/53
Date16.05.2018
Size5.49 Mb.
1   ...   21   22   23   24   25   26   27   28   ...   53

Results for other efficacy outcomes


In the updates with 23 October 2015 and 16 March 2015 cut-off dates, results were also presented for OR, ‘CBR’, DoR; with 112 (57% of the required 198 OS events) deaths at the most recent cut-off (23 October 2015), the OS data are too immature for analysis.
Objective response

In the ITT population OR (CR/PR) rates were higher in the treatment than the control arm, but in the analysis from the data cutoff date of 23 October 2015:

  • the ITT investigator-assessed OR rate was 21.0% (95% CI: 16.9-25.7) in the palbociclib plus fulvestrant arm and 8.6% (95% CI: 4.9-13.8) in the placebo plus fulvestrant arm;

  • the odds ratio was 2.78 (95% CI: 1.56-5.60) in favour of palbociclib plus fulvestrant treatment, with a stratified 1-sided p-value of 0.0001.

The sponsor provided additional analyses for endpoints that were not listed in the study design with this latest data cut-off, including the OR for patients with measurable disease.

Table 16: Study A5481023 Summary of objective response, clinical benefit response and duration of objective response – Investigator assessed as of 23 October 2015, ITT population



In the ITT population, 4 patients (2.9%) achieved a CR in the control arm compared with none (0%) in the treatment arm, while 21% in the treatment arm achieved a PR compared with 6.3% in the control arm. SD was reported in 52.5% (42.5%>24 weeks) of the palbociclib and fulvestrant arm compared with 41.3% (31%>24 weeks).

The objective progression rate (progression without any response) was 17% in the palbociclib and fulvestrant arm compared with 33% in the comparator arm.

Comment: For the first time, the OR is now statistically significantly improved in the palbociclib and fulvestrant arm. However, the OR for those with measurable disease was not a secondary endpoint and involves a subgroup analysis that was not prespecified and therefore should not be included in PI and the sponsor is requested to remove this in providing an updated PI.




Share with your friends:
1   ...   21   22   23   24   25   26   27   28   ...   53


The database is protected by copyright ©dentisty.org 2019
send message

    Main page